
Annual report 2023
added 12-27-2025
Profound Medical Corp. Revenue 2011-2026 | PROF
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.2 M | 6.68 M | 6.87 M | 7.3 M | 4.17 M | 2.6 M | 4.9 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.3 M | 2.6 M | 5.68 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.59 | -0.37 % | $ 92.7 B | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.07 | 0.33 % | $ 1.63 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.59 | 1.2 % | $ 36.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.7 | 0.73 % | $ 347 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.19 | 0.17 % | $ 47.5 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.6 | 0.05 % | $ 122 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.74 | -0.05 % | $ 5.47 K | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
AxoGen
AXGN
|
225 M | $ 32.64 | -5.23 % | $ 1.5 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.9 | 2.15 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
349 M | $ 6.36 | 2.42 % | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.0 | 1.66 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 95.66 | -0.59 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.63 | -1.4 % | $ 2.97 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Align Technology
ALGN
|
4 B | $ 171.87 | 0.74 % | $ 12.9 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.94 | -0.75 % | $ 374 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.38 | 0.11 % | $ 266 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.36 | 2.26 % | $ 55.3 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.28 | -0.4 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.88 | -1.02 % | $ 573 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.7 | 4.84 % | $ 29.3 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.77 | 2.08 % | $ 466 M | ||
|
PAVmed
PAVM
|
71 K | $ 10.04 | 1.93 % | $ 6.73 M |